-
By Cassie J. Edgar
On December 19th, the FDA issued a FDA declaratory order noting the resolution of the shortage for tirzepatide injection products, including Mounjaro and Zepbound. The tirzepatide shortage, which began in December 2022, was driven by overwhelming demand for these breakthrough medications used in managing type 2 diabetes and obesity. The FDA’s most recent decision, effective […]
By Luke T. Mohrhauser
As we approach the end of 2024, we hope you have had a successful and fulfilling year. I cannot help but think of what a milestone McKee, Voorhees & Sease had this year making it to our 100th anniversary, an achievement less than 1% of all law firms accomplish. We have exhibited snapshots of our […]
By Andrew J. Morgan
In its final rule issued on November 20, 2024, the United States Patent and Trademark Office (USPTO) issued changes to set or increase certain patent fees. The revised fees will take effect on January 19, 2025. There will not be a new fee for After Final Consideration Pilot 2.0 requests as was proposed, nor will […]
By Christine Lebron-Dykeman
On November 18, 2024, the USPTO issued a final rule to increase certain trademark filing fees. The fees will take effect January 18, 2025. While the per Class fee for filing a standard electronic trademark application has not changed and is still $350 per Class, the USPTO has eliminated the distinction between TEAS Standard and […]
Receive the latest news and updates from us and our attorneys.